High-Concentration

High-Concentration Biologics Are Redefining Subcutaneous Delivery

Pharma's Almanac

Drug Delivery

Intracellular Delivery: Reaching Targets Beyond the Cell Surface

David Alvaro, Ph.D.

Pharma's Almanac

Next-Gen Delivery

Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms

Pharma's Almanac

LAIs

The Long View: How Extended-Duration Therapies Are Reshaping Patient Care

Pharma's Almanac

LNP Strategy

Building Better RNA Medicines Through Smarter LNP Formulation Strategy

Aula Al Muslim, Ph.D.

Recipharm Advanced Bio

Pathfinder

Depot Injection vs. Implantable Drug Delivery: Which Long-Acting Delivery Strategy Is Better?

Pharma's Almanac

Peptides

The Resurgence of Peptide Drugs in the Age of Precision Medicine

David Alvaro, Ph.D.

Pharma's Almanac

Oligo Delivery

Expanding the Reach of Oligonucleotide Drugs Through Delivery Innovation

David Alvaro, Ph.D.

Pharma's Almanac

Oral mAbs

Oral Delivery of Monoclonal Antibodies: The Pursuit Continues

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Neuro CMC

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

David Alvaro, Ph.D.

Pharma's Almanac

BBB

Opening the Blood–Brain Barrier: Device-Based Strategies for CNS Drug Delivery

David Alvaro, Ph.D.

Pharma's Almanac

BBB

Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier

David Alvaro, Ph.D.

Pharma's Almanac

Long-Acting Delivery

Long-Acting Drug Delivery for Chronic Metabolic and Renal Conditions

David Alvaro, Ph.D.

Pharma's Almanac

Spray Drying

From Formulation Tool to Manufacturing Strategy: The Evolving Role of Spray Drying

Nick Hodgson

Codis

Drug Delivery

How Drug Delivery Choices Shape Regulatory Review Risk

David Alvaro, Ph.D.

Pharma's Almanac

Drug Delivery

Duration Is the New Potency: Why Exposure Control Is Replacing Peak Concentration

David Alvaro, Ph.D.

Pharma's Almanac

Drug Delivery

When Drug Delivery Fails at Tech Transfer

David Alvaro, Ph.D.

Pharma's Almanac

Oral Biologics

Oral Biologics and the Anatomy of a Persistent Challenge

David Alvaro, Ph.D.

Pharma's Almanac

LNPs

Expanding LNP Applications Beyond mRNA Vaccines

Jan Bekker; Phillip Elliott, Ph.D.; Jason Arcediano

BioCina

ssDNA

Leveraging the Therapeutic Potential of Single-Stranded DNA

Cynthia A. Challener, Ph.D.

Pharma's Almanac